Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Parkinson's disease explained: symptoms, causes and treatment

    Parkinson's disease is a nervous system disorder that affects movement and gets worse over time. Its main symptoms come from the loss of dopamine-producing brain cells.[1][2] There is no cure, but levodopa, other medicines, deep brain stimulation and rehabilitation can reduce symptoms, and the NHS says most people now have a normal or near-normal life expectancy.[3][4][5] WHO says global prevalence doubled in 25 years, to over 8.5 million people in 2019.[6]

    Editor reviewedStrict sourcingUpdated Explainer21 claims · 100% primaryHealth and medicine, Neuroscience and brain-computer interfaces
    Reading level: 1 passage differs; the rest is the same for everyone.

    This page explains Parkinson’s disease and its treatments. It is not medical advice. If you notice symptoms or have questions about Parkinson’s medicine, talk to a doctor or neurologist. This page gives no dosing information.

    Parkinson’s disease is a disorder of the nervous system that affects movement and gets worse over time.[1] WHO says the number of people living with it doubled over 25 years, to over 8.5 million worldwide in 2019.[6]

    What happens in the brain

    Most symptoms start when nerve cells in a brain area called the substantia nigra weaken and die. These cells make dopamine, a chemical messenger needed for smooth movement. By the time symptoms appear, most people have lost 60 to 80% or more of them.[2] Damaged brain cells in most people with Parkinson’s contain Lewy bodies, clumps of a protein called alpha-synuclein.[7]

    Symptoms

    The main movement symptoms are shaking (tremor), slow movement, stiff muscles and balance problems that can lead to falls.[8] Other symptoms can include depression and anxiety, sometimes before movement problems begin, and loss of the sense of smell.[9] WHO says many people with Parkinson’s also develop dementia.[10]

    NINDS lists four common motor features: tremor, rigidity, bradykinesia and postural instability.[8] Non-motor features include depression or anxiety, which may precede motor onset, and anosmia.[9] Dementia develops in many patients over the course of the disease.[10]

    Who gets it and why

    NINDS says the average age of onset is the early to mid-60s, with a small share of cases beginning before 50. Men are affected more often than women.[11] In most people the cause is unknown; WHO says exposure to air pollution, pesticides and solvents may increase risk.[12] Some cases are linked to genes such as SNCA, which makes alpha-synuclein and was the first gene tied to the disease, and LRRK2.[13]

    Diagnosis

    Parkinson’s is a clinical diagnosis based on symptoms and examination.[14] Two tests that detect alpha-synuclein, one in a small skin sample and one in spinal fluid, can support the diagnosis, but they cannot tell Parkinson’s from similar disorders such as multiple system atrophy. A DaT brain scan can also help.[14]

    Treatment

    There is no cure, but medicines, surgery and rehabilitation can reduce symptoms.[3]

    • Levodopa. The main therapy is levodopa, which the brain converts to dopamine. It is combined with carbidopa so that more of it reaches the brain.[4] As the disease progresses, symptoms can return before the first dose of the day and between doses.[15] NINDS says people should never stop carbidopa-levodopa without talking to a doctor, because stopping suddenly can have potentially serious side effects.[16]
    • Other medicines. Dopamine agonists act like dopamine in the brain, while MAO-B and COMT inhibitors slow its breakdown.[17]
    • Deep brain stimulation (DBS). A surgeon places a thin wire carrying electrical signals in a movement-control area of the brain. It is usually considered when medicines stop working well or cause difficult side effects.[5]
    • Exercise and rehabilitation. Physical activity can improve flexibility, balance and strength, and WHO says physiotherapy can offer relief.[18]

    WHO notes that levodopa/carbidopa, the most effective medicine for symptoms, is not accessible or affordable everywhere, especially in low- and middle-income countries.[19]

    Outlook

    The NHS says that with advances in treatment, most people with Parkinson’s now have a normal or near-normal life expectancy.[3] See also epilepsy and multiple sclerosis, two other common neurological conditions, which WHO describes as affecting around 50 million and over 1.8 million people worldwide.[20][21]

    More in Health & medicine

    Questions readers ask

    What causes Parkinson's disease?

    In most people the cause is unknown. Researchers think genes and environment both play a part, and WHO says exposure to air pollution, pesticides and solvents may increase risk. Symptoms come from the loss of dopamine-producing cells in the substantia nigra.[12][2]

    What are the early signs?

    Common movement symptoms are tremor, slowness, stiffness and balance problems. Depression or anxiety can appear early, even before movement problems, and loss of smell is another recognised symptom.[8][9]

    At what age does Parkinson's usually start?

    NINDS says the average age of onset is the early to mid-60s, a small share of cases begin before 50, and men are affected more often than women.[11]

    Is there a test for Parkinson's?

    It is mainly a clinical diagnosis. Skin and spinal fluid tests for alpha-synuclein and a DaT brain scan can help, but the alpha-synuclein tests cannot tell Parkinson's from similar disorders.[14]

    Is Parkinson's fatal?

    The NHS says that with advances in treatment, most people with Parkinson's now have a normal or near-normal life expectancy, although there is no cure.[3]

    What is deep brain stimulation?

    It is brain surgery in which a thin wire carrying electrical signals is placed in a movement-control area of the brain. It is usually considered when medicines stop working well or cause difficult side effects.[5]

    Sources

    · 21 claims from 3 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      Parkinson's disease is a disorder of the nervous system that affects movement and gets worse over time. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · What is Parkinson's disease? (retrieved 2026-11-07)
      • Parkinson disease (fact sheet) · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
    2. [2]

      Most symptoms come from the loss of dopamine-producing cells in the substantia nigra; by the time symptoms appear, most people have lost 60 to 80% or more of them. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · PD and the brain (retrieved 2026-11-07)
      • Parkinson's disease · NHS · Primary source · Causes (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · PD and the brain (retrieved 2026-11-07)
    3. [3]

      There is no cure, but with modern treatment the NHS says most people with Parkinson's now have a normal or near-normal life expectancy. confirmedas of 2026-11-07

    4. [4]

      The main therapy is levodopa, combined with carbidopa so that more reaches the brain, where it is converted to dopamine. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Carbidopa-levodopa (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Carbidopa-levodopa (retrieved 2026-11-07)
      • Parkinson disease (fact sheet) · World Health Organization · Primary source · Treatment and care (retrieved 2026-11-07)
    5. [5]

      Deep brain stimulation, in which a surgeon places a thin wire carrying electrical signals into a movement-control area of the brain, is usually considered after medicines stop working well or cause difficult side effects. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Deep brain stimulation (retrieved 2026-11-07)
      • Parkinson disease (fact sheet) · World Health Organization · Primary source · Treatment and care (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Deep brain stimulation (retrieved 2026-11-07)
    6. [6]

      WHO says the global prevalence of Parkinson's doubled over 25 years, with over 8.5 million people living with it in 2019. confirmedas of 2019-12-31

    7. [7]

      Damaged brain cells in most people with Parkinson's contain Lewy bodies, clumps of the protein alpha-synuclein. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · PD and the brain (retrieved 2026-11-07)
    8. [8]

      The main movement symptoms are tremor, slow movement (bradykinesia), stiff muscles and balance problems. confirmedas of 2026-11-07

      • Parkinson's disease · NHS · Primary source · Symptoms (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Symptoms of PD (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Symptoms of PD (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Symptoms of PD (retrieved 2026-11-07)
      • Parkinson's disease · NHS · Primary source · Symptoms (retrieved 2026-11-07)
    9. [9]

      Non-movement symptoms can include depression and anxiety, which may begin before movement problems, as well as loss of smell, sleep problems and memory problems. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Mental and emotional health problems (retrieved 2026-11-07)
      • Parkinson's disease · NHS · Primary source · Symptoms (retrieved 2026-11-07)
      • Parkinson's disease · NHS · Primary source · Symptoms (retrieved 2026-11-07)
    10. [10]

      WHO says many people with Parkinson's also develop dementia. confirmedas of 2026-11-07

    11. [11]

      Parkinson's typically starts in a person's early to mid-60s, a small share of cases begin before 50, and men are affected more often than women. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Risk factors, Age (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Risk factors, Biological sex (retrieved 2026-11-07)
      • Parkinson's disease · NHS · Primary source · Who's affected (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Risk factors, Age (retrieved 2026-11-07)
    12. [12]

      In most people the cause is unknown; researchers think genes and environment both contribute, and WHO says exposure to air pollution, pesticides and solvents may increase risk. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Causes (retrieved 2026-11-07)
      • Parkinson disease (fact sheet) · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Causes (retrieved 2026-11-07)
    13. [13]

      Genes linked to Parkinson's include SNCA, which makes alpha-synuclein and was the first gene linked to the disease, and LRRK2. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Genes linked to PD (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Genes linked to PD (retrieved 2026-11-07)
    14. [14]

      Parkinson's is a clinical diagnosis; tests such as the Syn-One skin test and the SAAmplify spinal fluid test detect alpha-synuclein but cannot tell Parkinson's from similar disorders, and a DaT scan can help diagnose it. confirmedas of 2026-11-07

      • Parkinson disease (fact sheet) · World Health Organization · Primary source · Assessment and disease burden (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Diagnosis (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Diagnosis (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Diagnosis (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Diagnosis (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Diagnosing PD (retrieved 2026-11-07)
    15. [15]

      As the disease progresses, symptoms can return before the first dose of the day and between doses. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Carbidopa-levodopa (retrieved 2026-11-07)
    16. [16]

      NINDS says people with Parkinson's should never stop carbidopa-levodopa without talking to a doctor, because stopping suddenly can have potentially serious side effects. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Carbidopa-levodopa (retrieved 2026-11-07)
    17. [17]

      Other drug classes include dopamine agonists, which act like dopamine, and MAO-B and COMT inhibitors, which slow the breakdown of dopamine. confirmedas of 2026-11-07

      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Dopamine agonists (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · MAO-B inhibitors (retrieved 2026-11-07)
      • Parkinson's Disease · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · COMT inhibitors (retrieved 2026-11-07)
    18. [18]

      Physical activity and rehabilitation, including physiotherapy, strength training and gait and balance training, can help people with Parkinson's. confirmedas of 2026-11-07

    19. [19]

      WHO says levodopa/carbidopa, the most effective medicine for Parkinson's symptoms, is not accessible or affordable everywhere, particularly in low- and middle-income countries. confirmedas of 2026-11-07

    20. [20]

      WHO describes epilepsy as a chronic noncommunicable brain disease affecting around 50 million people worldwide, characterised by recurrent seizures. confirmedas of 2026-11-07

    21. [21]

      WHO estimates that over 1.8 million people worldwide have MS. confirmedas of 2026-11-07

    Revision history (1)
    1. Page created.

    Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: May 7, 2027.

    Cite this page

    "Parkinson's disease explained: symptoms, causes and treatment." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/parkinsons-disease-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.